EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy | MicrobiomeTrials
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2023-12-01Est. Completion: 2026-05-13
Enrollment target: 64 participants
Locations
Research Site, Beijing, China
Research Site, Beijing, China
Research Site, Beijing, China
Research Site, Beijing, China
Research Site, Beijing, China
Research Site, Changsha, China
Research Site, Changsha, China
Research Site, Changsha, China
Research Site, Chengdu, China
Research Site, Chengdu, China
Research Site, Chongqing, China
Research Site, Chongqing, China
Research Site, Guangzhou, China
Research Site, Guangzhou, China
Research Site, Hangzhou, China
Research Site, Hangzhou, China
Research Site, Hangzhou, China
Research Site, Ha’erbin, China
Research Site, Jinan, China
Research Site, Nanchang, China
Research Site, Shanghai, China
Research Site, Suzhou, China
Research Site, Taiyuan, China
Other microbiome trials you might be interested in